Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer (TOP0706)

Clinical Trial ID NCT00564876

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00564876

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006 7.45
2 Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006 6.69
3 Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet 2003 3.78
Next 100